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Abstract: 
The soy-derived phytoestrogen genistein has received attention for its potential to improve 
vascular function, but its mechanism remains unclear. Here, we report that genistein at 
physiologically relevant concentrations (0.1–10 μM) significantly inhibited thrombin-induced 
increase in endothelial monolayer permeability. Genistein also reduced the formation of stress 
fibers by thrombin and suppressed thrombin-induced phosphorylation of myosin light chain 
(MLC) on Ser19/Thr18 in endothelial cells (ECs). Genistein had no effect on resting intracellular 
[Ca2+] or thrombin-induced increase in Ca2+ mobilization. Addition of the inhibitors of 
endothelial nitric oxide synthase or estrogen receptor did not alter the protective effect of 
genistein. RhoA is a small GTPase that plays an important role in actin-myosin contraction and 
endothelial barrier dysfunction. RhoA inhibitor blocked the protective effect of genistein on 
endothelial permeability and also ablated thrombin-induced MLC-phosphorylation in ECs. 
Inhibition of PKA significantly attenuated the effect of genistein on thrombin-induced EC 
permeability, MLC phosphorylation, and RhoA membrane translocation in ECs. Furthermore, 
thrombin diminished cAMP production in ECs, which were prevented by treatment with 
genistein. These findings demonstrated that genistein improves thrombin-induced endothelial 
barrier dysfunction in ECs through PKA-mediated suppression of RhoA signaling. 
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Article: 
Cardiovascular diseases, especially atherosclerosis, are the major cause of morbidity and 
mortality in the industrialized world and claim the lives of over 40% of the nearly 2.4 million 
Americans who die each year (1). Vascular inflammation and endothelial barrier dysfunction-
induced vascular permeabilities play a fundamental role in the initiation and progression of 
atherosclerosis. Indeed, the development of atherosclerosis is associated with increased 
permeability of vascular endothelial monolayers for macromolecules such as low-density 
lipoprotein (2). Thrombin is a multifunctional serine protease generated at the site of vascular 
injury, which plays a significant role in inflammatory diseases and endothelial barrier 
dysfunction. Thrombin elevates intracellular Ca2+ concentration and thereby activates 
Ca2+/calmodulin-dependent myosin light chain (MLC) kinase, leading to the phosphorylation of 
MLC and cell contraction (3, 4). Previous studies show that thrombin-induced endothelia cell 
(EC) permeability is mediated through RhoA, a GTPase. RhoA and its kinase inhibit 
dephosphorylation of MLC, thereby leading to MLC phosphorylation and cell contraction, 
resulting in increased vascular permeability (5). As such, RhoA signaling may be a potential 
target for preventing thrombin-induced endothelial barrier dysfunction. 
Genistein, an important soy-derived phytoestrogen, has received wide attention because of its 
potential beneficial effects on various human degenerative diseases, such as cardiovascular 
diseases. Genistein has a weak estrogenic effect (6) by binding to estrogen receptors (ERs) (7) 
and by inhibiting protein tyrosine kinase (PTK) (8). Recent human intervention studies suggest a 
beneficial effect of genistein on atherosclerosis (9), markers of cardiovascular risk (10, 11), 
vascular motor tone (12, 13), vascular endothelial function (14), and systemic arterial 
compliance (15). However, the effect of genistein on plasma lipid profiles, such as low-density 
lipoprotein and triglycerides, has been found to be essentially neutral (13, 15, 16), suggesting 
that the antiatherogenic effect of genistein is not due to a change in plasma lipids. Data from 
animal and in vitro studies also suggest a protective role of genistein in the vasculature (17, 18). 
Studies demonstrate that genistein has antiatherogenic effects by inhibiting proliferation of 
vascular endothelial (19) and smooth muscle cells (20). While these data are of great interest, 
most of the results in these studies reflected a pharmacological effect of genistein (>30 μM) that 
are well above the achievable plasma genistein concentrations (≤5 μM) in both rodents and 
humans following the consumption of genistein (21, 22). Recently, we have reported that 
genistein at physiological relevant concentrations (≤5 μM) reduce hyperglycemia-induced 
vascular inflammation in ECs (23). While this study supports a vascular-protective effect of 
genistein, the effect and molecular mechanisms of genistein on thrombin-induced endothelial 
permeability remains unknown. 
Cyclic AMP is a central signaling molecule in a variety of cellular systems and plays an 
important role in maintaining normal vascular function (24–27). We have recently demonstrated 
that genistein at physiologically achievable doses directly acts on vascular ECs, leading to 
accumulation of intracellular cAMP and subsequent activation of protein kinase A (PKA) (28). 
The activation of the cAMP-signaling system is not related to any known action of genistein, 
such as inhibition of PTK or binding to ERs (28, 29), suggesting a novel effect of genistein on 
vasculature. Cyclic AMP/PKA signaling has been suggested to play a very important role in 
maintaining normal vascular function by inhibiting vascular endothelial from proinflammatory 
cytokine-induced damage (24), depressing leukocyte adhesion to ECs (25), and maintaining 
normal endothelial barrier function (26, 27). However, the molecular action of genistein on 
endothelial barrier dysfunction is unknown. In this study, we investigated the hypothesis that 
genistein protects thrombin-induced endothelial barrier dysfunction through cAMP/PKA-
mediated suppression of RhoA signaling. 
Materials and Methods 
Materials 
Bovine aortic endothelial cells (BAECs) and vascular endothelial growth factors were from 
Lonza Walkersville, Inc. (Walkersville, MD); M199 media, fetal bovine serum (FBS), L-
glutamine, penicillin-streptomycin, Fura-2AM, and phalloidin Alexa-488 were purchased from 
Invitrogen (Carlsbad, CA); RhoA, phosphor-specific MLC and MLC antibodies were from Cell 
Signaling Inc. (Danvers, MA); nitrocellulose membranes were from Schleicher & Schuell 
(Keene, NH); superSignal chemiluminescence detection system, stripping buffer, and avidin-
conjugated fluorescein (avidin-FITC) were purchased from Pierce (Rockville, IL); fibronectin-
coated Transwell plates were obtained from BD Bioscience Labware (Boston, MA); cAMP 
enzyme immunoassay (EIA) kit was from Assay Design Inc. (Ann Arbor, MI); ICI 182,780 (ICI) 
was purchased from Tocris Cookson (Balwin, MO); genistein (from soybean, ≥98%, HPLC), 
H89, α-thrombin, C3-transferase (C3), NG-nitro-L-arginine methyl ester (L-NAME), protease 
inhibitor cocktail, phosphatase inhibitor cocktail I, 8-Bromo-cAMP, and general chemicals were 
from Sigma-Aldrich (St. Louis, MO). 
Cell culture 
BAECs were grown in M199 medium supplemented with 20% FBS, 50 U/ml penicillin, and 0.05 
mg/ml streptomycin and incubated at 37°C in a 5% CO2, 95% air environment. Medium was 
changed every second day until confluence. BAECs were serially passaged after 0.05% trypsin 
treatment and passages 4-8 were used in all experiments. Before experiments, cells were cultured 
for 24 h in M199 medium containing 10% FBS and subsequently, BAECs were serum-starved in 
M199 medium containing 1% FBS and 0.5% bovine serum albumin (BSA) for 12 h. For 
endothelial barrier permeability study, BAECs were cultured on fibronectin-coated 
polycarbonate filters (0.6 cm, 3 μm pore size) of the Transwell plate in M199 medium with 20% 
FBS for 3-4 d until a tight monolayer formed. Before experiment, cells were kept in M199 
medium containing 10% FBS for 12 h and then were washed and incubated in medium 
containing 1% FBS for 2 h. 
Evaluation of endothelial barrier function in ECs 
To evaluate the protective effect of genistein against thrombin-induced endothelial barrier 
dysfunction, we measured avidin-FITC (∼64 kD) passage cross the endothelial monolayer, an 
established in vitro model for study of endothelial permeability. Passage of avidin-FITC through 
BAEC monolayers, as an index of barrier function, was assessed as described previously 
(30, 31). BAECs were cultured on fibronectin-coated polycarbonate porous filters and treated 
with genistein, or vehicle (dimethylsulfoxide) in medium containing 1% serum for 30 minutes at 
37°C. In some experiments, cells were preincubated with or without 0.3 mM endothelial nitric 
oxide synthase (eNOS) inhibitor L-NAME, 1 μM estrogen receptor antagonist ICI for 30 
minutes, 5 μg/ml RhoA inhibitor C3 for 24 h, or 10 μM PKA-specific inhibitor H89 for 30 
minutes prior to addition of 5 μM genistein for 30 minutes. Thrombin (2U/ml) and avidin-FITC 
(1 μM) were then added to the upper compartment of the Transwells in the continued presence of 
genistein or vehicle for 1 hour. Samples were taken from the bottom compartment and the 
concentration of avidin-FITC in each sample was determined using a fluorometer plate reader 
(BMG Labtech, Inc, Durham, NC). Passage rates were expressed as nanogram per square 
centimeter per hour (31). 
Assessment of cytoskeleton changes in ECs 
BAECs were incubated in 4-well glass chamber slides in M199 medium near confluence, and 
serum-starved for 24 hours. Cells were then treated with genistein or vehicle in phenol-red free 
medium for 10 minutes at 37°C. Afterward, thrombin (2U/ml) was added to the medium in the 
continued presence of genistein or vehicle for 5 minutes. Cells were then fixed with 
paraformaldehyde for 10 minutes at room temperature. After three washes in PBS, fixed cells 
were permeabilized with 0.1% Triton X-100 for 1 minute at room temperature. After a new 
series of three washes in PBS, cells were incubated with phalloidin Alexa-488 (dilution: 1:100 in 
PBS) for 1 hour and were then observed with a computer-operated Nikon Fluorescence 
microscope (Nikon, Japan). Images were acquired with a high-resolution color camera (Nikon, 
Japan). 
Intracellular calcium concentration ([Ca2+]) measurement 
The concentration of cytosolic free [Ca2+] was measured using the intracellular fluorescent 
Ca2+ probe of Fura-2 AM as previously described (32, 33). Briefly, confluent BAECs were 
loaded with 1 μg/mL of Fura-2 AM at 37°C in culture medium for 30 minutes and then washed 
and placed in PBS containing 20 mM HEPES. The cells were preincubated with various 
concentrations of genistein or vehicle for 30 minutes at 37°C and were then treated with or 
without 2 U/ml thrombin in the continued presence of genistein for 10 minutes. Fura-2 AM 
fluorescence data were obtained at an emission wavelength of 505 nm, with alternating 
excitation wavelengths of 340 and 380 nm, using a dual- excitation monochromator. 
Intracellular cAMP assay 
The accumulation of cAMP in BAECs was determined by a specific EIA assay kit. Serum-
starved BAECs were preincubated with Hank's balanced salt solution buffer and then treated 
with 5 μM genistein or vehicle at 37°C; 30 minutes later, thrombin (2 U/ml) was added to cell 
culture in the continued presence or genistein or vehicle for 5 minutes. After treatment period, 
the supernatant was rapidly aspirated and intracellular cAMP content was measured as we 
previously described (28). 
Analysis of MLC phosphorylation and RhoA activation in ECs 
Following experimental treatment, BAECs were harvested by scraping into lysis buffer (20 mM 
Tris/HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM 
Na4P2O7, 1 mM β-glycerolphosphate, 1 mM Na3VO4), supplemented with protease inhibitor 
cocktail (1:500) and phosphatase inhibitor cocktail I (1:100). The extracts were sonicated and 
centrifuged at 10,000 × g for 5 minutes. Protein levels were measured using a Bio-Rad assay kit. 
Detergent-extracted proteins were mixed with Laemmli sample buffer, heated for 5 minutes at 
95°C, and equal amounts of cell lysate proteins (50 μg) were resolved on 10% SDS-PAGE gels. 
The gels were blotted onto nitrocellulose membranes, probed with rabbit anti-phospho-MLC 
(Thr18/Ser19), mouse anti-MLC, or rabbit anti-RhoA primary antibodies overnight at 4°C, and 
incubated with secondary antibody conjugated to horseradish peroxidase for 1 hour at room 
temperature. The immunoreactive proteins were detected by superSignal chemiluminescence. 
The protein bands were digitally imaged for densitometric quantitation with a software program 
(Silk Scientific, Inc., Orem, UT). The amount of phosphorylated MLC was normalized with the 
total MLC contents from the same sample. 
Statistical analysis 
All data were subjected to one-way ANOVA analysis using Sigmaplot® software, and treatment 
differences were subjected to Tukey's multiple-comparison tests, where P < .05 was considered 
significantly different. Values are expressed as mean ± standard error (SE). 
Results 
Genistein prevents thrombin-induced endothelial barrier dysfunction 
Treatment of thrombin significantly induced endothelial barrier dysfunction in ECs as shown by 
an increase in avidin-FITC passage (Figure 1A). Genistein pretreatment at 0.1 μM, 1 μM, and 10 
μM concentrations reduced thrombin-induced increase in avidin-FITC passage by 31%, 37%, 
and 49%, respectively (P < .05) (Figure 1A). The actin cytoskeleton of ECs is important in 
maintaining the structural integrity of ECs, and thrombin-induced EC contraction is associated 
with increased formation of F-actin stress fiber (34). We further evaluated thrombin-induced 
cytoskeletal reorganization using fluorescence microscopy. Thrombin induced a dramatic 
increase in the formation of stress fibers in ECs (Figure 1B). Treatment with genistein prevented 
the formation of stress fibers, suggesting that genistein can prevent the thrombin-induced 
changes in the EC cytoskeleton (Figure 1B). Phosphorylation of MLC is a key mechanism by 
which thrombin signals are converted into the mechanochemical force for cell contraction (3). 
We then tested whether genistein suppresses thrombin-induced MLC phosphorylation in ECs. 
Exposure of ECs to thrombin leads to the phosphorylation of MLC on Ser19/Thr18. However, 
genistein treatment blocked the thrombin-induced MLC phosphorylation (Figure 1C). To 
determine whether this genistein effect is only restricted to thrombin, we further examined the 
effect of genistein on tumor necrosis factor (TNF)–α induced endothelial monolayer permeability 
in ECs. Genistein similarly suppressed TNF-α-stimulated monolayer permeability (data is not 
shown), further conforming the protective effect of genistein on acute inflammatory mediator-
induced endothelial barrier dysfunction. 
 
Figure 1. Genistein protects thrombin-induced EC barrier dysfunction. A, BAEC monolayers 
were preincubated with various concentrations of genistein (G) or vehicle (C) for 30 minutes. 
Cells were then treated with or without 2U/ml thrombin (T) in the continued presence of 
genistein for 1 hour and avidin-FITC passage was measured. B, BAECs were preincubated with 
genistein (G, 5 μM) or vehicle (C) for 30 minutes, followed by stimulation with thrombin (T; 2 
U/ml) for 5 minutes. Cells were then fixed with paraformaldehyde, permeabilized with Triton X-
100, and stained with Alexa-phalloidin, and viewed with a digital fluorescence microscope. C, 
BAECs were preincubated with indicated concentrations of genistein for 30 minutes, followed 
by stimulation with thrombin (T; 2 U/ml) for 5 minutes. Phosphorylation of MLC (upper panel) 
and total MLC (lower panel) were detected by Western blot. Data are expressed as mean ± SE of 
four different experiments, each performed in duplicate. *P < .05 vs control; †P < .05 vs 
thrombin-alone-treated cells. 
Genistein did not affect thrombin-induced intracellular calcium release 
It is well established that thrombin elevates intracellular Ca2+ concentration and thereby activates 
Ca2+/calmodulin-dependent MLC kinase, leading to the phosphorylation of MLC and cell 
contraction (3, 4). We tested whether genistein protective action against thrombin-induced 
endothelial permeability is associated with the inhibition of thrombin-induced increased in 
intracellular [Ca2+]. Genistein (10 nM to 10 μM) did not alter either resting [Ca2+] or thrombin-
induced increase in Ca2+ mobilization (Figure 2), suggesting that the protective effect of 
genistein against thrombin-induced endothelial barrier dysfunction is not mediated via reducing 
intracellular [Ca2+]. 
 
Figure 2. Genistein does not affect thrombin-induced intracellular calcium release in BAECs. 
BAECs were loaded with 1 μg/mL of fura-2 AM (30 min at 37°C in culture medium). The cells 
were preincubated with various concentrations of genistein (G) or vehicle (C) for 30 minutes at 
37°C and were then treated with or without 2 U/ml thrombin (T) for 5 minutes. [Ca2+] was 
measured in fura-2 loaded BAECs at an emission wavelength of 505 nm with alternating 
excitation wavelengths of 340 and 380 nm. Data are expressed as mean ± SE from three 
independent experiments, each assayed in duplicate. *P < .05 vs vehicle-treated control. 
Effect of genistein on thrombin-induced endothelial permeability is not mediated through 
nitric oxide (NO) 
Previous studies have shown that NO can attenuate thrombin-induced endothelial permeability 
through cGMP-mediated inhibition of phosphodiesterase III or intracellular Ca2+accumulation 
(35). We assessed whether genistein activity on endothelial permeability is mediated via NO. 
Inhibition of NO production by L-NAME enhanced the thrombin-induced increase in endothelial 
permeability (Figure 3). In the presence of L-NAME, the protective action of genistein against 
thrombin-induced endothelial permeability was attenuated by about 20% (Figure 3), suggesting 
the existence of an alternative mechanism, which may more importantly mediate genistein 
activity that counteracts the barrier disruptive effects of thrombin. 
 
Figure 3. Inhibition of NO did not block the effect of genistein on thrombin-induced endothelial 
permeability. BAEC monolayers were preincubated with or without 0.3 mM Nϖ-nitro-L-arginine 
methyl ester (L-NAME) for 30 minutes, then with the presence of 5 μM genistein (G) for 30 
minutes, followed by addition of 2 U/ml thrombin (T) for 1 hour. Avidin-FITC passage was 
measured, and data are expressed as mean ± SE of three different experiments, each performed 
in duplicate. *P < .05 vs thrombin alone-treated cells; †P < .05 vs T+G-treated cells; #P < .05 vs 
L-NAME + T-treated cells. 
Effect of genistein on thrombin-induced endothelial permeability is independent of ERs or 
PTK 
Because genistein has weak estrogenic effects in some tissues by binding to ERα and ERβ (6), 
we examined whether this genistein effect is mediated via ERs. The ER antagonist ICI 182,780, 
which successfully inhibited the effect of 17β-estradiol in ECs in our previous study (29), did not 
inhibit the protective effect of genistein on thrombin-induced endothelial permeability (Figure 
4A), suggesting that genistein activity is not mediated through ERs. Genistein is an inhibitor of 
PTK (36). However, our previous studies have shown that genistein at low concentrations (10 
nM to 10 μM) had no effect on the basal or endothelial growth factor–induced PTK activity (29). 
Genistein only inhibits PTK at 100-μM concentration (29, 37). We further compared the effect of 
genistein with that of daidzein, an analog of genistein that is inactive for PTK inhibition, on 
thrombin-induced endothelial permeability. As shown in Figure 4B, daidzein also ameliorated 
thrombin-induced endothelial barrier dysfunction, although to a slightly lesser degree than did 
genistein. These results suggest that genistein action against thrombin-induced endothelial 
barrier dysfunction is not mediated through inhibition of PTK. 
 
Figure 4. The effect of genistein on thrombin-induced endothelial permeability is independent of 
ERs or PTK. A, BAEC monolayers were preincubated with or without (C) ICI 182,780 (I) for 30 
minutes, then with the presence of 5 μM genistein (G) for 30 minutes, followed by addition of 2 
U/ml thrombin (T) for 1 hour. B, BAEC monolayers were pretreated with 5 μM genistein (G) or 
daidzein (D) for 30 minutes prior to addition of 2 U/ml thrombin (T) for 1 hour. Avidin-FITC 
passage was measured, and data are expressed as mean ± SE of three different experiments, each 
performed in duplicate. *P < .05 vs control; †P < .05 vs thrombin-alone-treated cells. 
Genistein suppression of thrombin-induced EC permeability is mediated via RhoA in ECs 
To analyze whether RhoA is involved in EC contraction, we measured thrombin-stimulated 
increase in vascular permeability in the absence or presence of the specific RhoA inhibitor C3-
transferase (C3). Preincubation of the cells with C3 inhibited thrombin-induced endothelial 
permeability, whereas heat-inactivated C3 had no such an effect (Figure 5A). Consistently, 
active C3 but not the heat-inactivated C3 ablated thrombin-induced MLC phosphorylation 
(Figure 5B), suggesting that RhoA plays an important role in mediating thrombin-induced 
endothelial barrier dysfunction. The activity of RhoA is regulated by GDP/GTP cycling. Once 
activated, RhoA releases bound GDP in exchange for GTP and translocates to plasma 
membranes from cytosolic fractions (31, 38, 39). To further confirm the role of RhoA in 
mediating the inflammatory action of thrombin, we measured RhoA membrane translocation in 
the presence or absence of genistein. Incubation of ECs with thrombin greatly induced RhoA 
membrane translocation, which was diminished by genistein treatment. Dose-response studies 
showed that genistein as low as 0.1 μM attenuated RhoA activation, with a maximal effect at 10 
μM genistein, which was also significantly more potent than ≤5 μM genistein (Figure 5, C-E). 
Consistently, the addition of genistein did not produce further inhibitory effect of C3 on 
thrombin-induced endothelial permeability (Figure 5F). Together, these results indicate that 
genistein may protect vascular barrier function through inhibition of RhoA signaling-mediated 
MLC phosphorylation. 
 
Figure 5. The effect of genistein on thrombin-induced endothelial permeability is mediated by 
inhibition of RhoA[b]. A, BAEC monolayers were incubated for 24 h with 5 μg/ml C3 
transferase (C3), heat-inactivated C3 (IC3), or vehicle (C), followed by addition of 2 U/ml 
thrombin (T) for 1 hour to stimulate and measure avidin-FITC passage. B, BAECs were 
preincubated with 5 μg/ml C3 transferase (C3), inactivated C3 (IC3), or vehicle (C) for 24 hours. 
Cells were then stimulated with thrombin (T; 2 U/ml) for 5 minutes. Phosphorylation of MLC 
(P-MLC) and total MLC were detected by Western blot. Representative images from three 
independent experiments with similar results are shown. C–E, BAECs were preincubated with 5 
μg/ml C3 transferase (C3), inactivated C3 (IC3), or vehicle (C) for 24 hours. The cells were then 
incubated with genistein (G, 0.1–10 μM) for 30 minutes prior to addition of thrombin (T; 2 
U/ml) for 5 minutes. The plasma membranes (PM) and cytoplasm (Cyto) of the cells were 
isolated, and RhoA in the PM, cytosol, and whole cell extracts (Total) were detected by Western 
blots. F, BAEC monolayers were incubated with 5 μg/ml C3 transferase (C3) or vehicle (C) for 
24 hours, followed by the addition of 5 μM genistein (G) for 30 minutes before stimulation with 
2 U/ml thrombin (T) for 1 hour. Avidin-FITC passage was measured. All data are expressed as 
mean ± SE of four independent experiments, each performed in duplicate.*P < .05 vs control; 
†P < .05 vs thrombin-alone-treated cells; #P < .05 vs ≤5 μM genistein-treated cells (D) or ≤ 1 
μM genistein-treated cells (E). 
The inhibitory effect of genistein on RhoA and endothelial barrier dysfunction are 
mediated by PKA 
The cAMP/PKA signaling pathway was shown to decrease isometric tension development, 
intercellular gap formation, and vascular permeability in multiple experimental preparations 
(27, 40–43). Our recent study showed that genistein activates the cAMP signaling system in ECs 
(28). We investigated whether the cAMP/PKA signaling pathway is involved in the protective 
action of genistein against thrombin-induced-RhoA membrane translocation, MLC 
phosphorylation, and EC permeability. Inhibition of PKA by H89, a selective PKA inhibitor, 
abolished the inhibitory effects of genistein on thrombin-induced RhoA membrane translocation 
(Figure 6A) and MLC phosphorylation (Figure 6B) in ECs. The addition of PKA inhibitor 
significantly attenuated the protective effect of genistein against thrombin-induced EC 
permeability (Figure 6C). Furthermore, genistein stimulated intracellular cAMP accumulation in 
ECs (Figure 6D), which is consistent with our previous finding (28). Interestingly, thrombin 
greatly reduced intracellular cAMP levels in ECs (Figure 6D). However, coincubation with 
genistein largely prevented this detrimental effect of thrombin (Figure 6D). To confirm the role 
of cAMP in regulating endothelial barrier function and RhoA activity, we further examined the 
effect of 8-bromo-cAMP, a cell-permeable cAMP analog that is widely used in studies related to 
cAMP-mediated cellular events (44), on thrombin-induced endothelial permeability and RhoA 
activation. 8-Bromo-cAMP significantly reduced the thrombin-induced increase in avidin-FITC 
passage (Figure 6E) and diminished the activity of RhoA membrane translocation in ECs (Figure 
6F), the effects that slightly more potent than those of genistein, suggesting that cAMP signaling 
plays an important role in maintaining endothelial barrier function and regulating RhoA activity 
in ECs. These results suggest that genistein inhibition of RhoA and endothelial barrier 
dysfunction is largely mediated via the cAMP/PKA pathway. 
 
Figure 6. Genistein inhibition of RhoA and endothelial barrier dysfunction is mediated via PKA. 
BAECs were preincubated for 30 minutes with 10 μM H89 (H) or vehicle, followed by addition 
of 5 μM genistein (G) for 30 minutes prior to stimulation with 2 U/ml thrombin (T) for 5 
minutes. Cells were then used for measuring RhoA in the plasma membranes (PM) and whole 
cell extracts (panel A) or for detecting the phosphorylated MLC (P-MLC) and total MLC (panel 
B). Representative images and quantitative data from four independent experiments are shown. 
Panel C, BAEC monolayers were preincubated with 10 μM H89 (H) or vehicle for 30 minutes, 
followed by the addition of 5 μM genistein (G) for 30 minutes prior to stimulation with 2 U/ml 
thrombin (T) for 1 hour. Avidin-FITC passage was measured. Panel D, BAECs were 
preincubated with 5 μM genistein (G) or vehicle for 30 minutes followed by the addition of 2 
U/ml thrombin (T) for 5 minutes. Intracellular cAMP was measured by EIA. Panel E, BAEC 
monolayers were preincubated with 0.5 mM 8-bromo-cAMP (B) or 5 μM genistein (G) for 30 
minutes. The thrombin-stimulated monolayer permeability was measured. Panel F, BAECs were 
preincubated with 0.5 mM 8-bromo-cAMP (B) or 5 μM genistein (G) for 30 minutes prior to the 
addition of thrombin (T; 2 U/ml) for 5 minutes. RhoA in the plasma membranes (PM) and whole 
cell extracts (Total) were detected by Western blots. Data are expressed as mean ± SE of 3-4 
independent experiments, each performed in duplicate. *P < .05 vs control; †P < .05 vs 
thrombin-alone-treated cells. 
Discussion 
Vascular inflammation and endothelial barrier dysfunction-induced vascular permeability play a 
fundamental role in the initiation and progression of atherosclerosis. Thrombin produced by the 
injured endothelium induces endothelial contraction and simultaneous cytoskeletal 
rearrangements, which promote intercellular gap formation that leads to increases in vascular 
permeability (3, 34). In the present study, we showed that genistein suppresses thrombin-induced 
increase in endothelial monolayer permeability via inhibition of MLC phosphorylation and 
RhoA membrane translocation. This action of genistein is independent of [Ca2+], PTK, and ERs 
but dependent on PKA. Unlike many previously published in vitro studies in which high doses of 
genistein were used with the results therefore reflecting a pharmacological rather than 
physiological actions of this phytoestrogen, the effective dose of genistein observed in the 
present study is likely physiologically relevant. Human studies reported that serum genistein 
levels can reach 4.6 and 4.1 μM, following consumption of three meals per day containing soy 
milk and a single soy meal, respectively (21, 22). The serum concentrations of genistein were 
reported to be 0.16–0.89 μM (45) in Japanese men consuming soy products. In the present study, 
genistein at a very low concentration (0.1 μM) ameliorated thrombin-induced increase in 
endothelial monolayer permeability. Therefore, the findings in the present study demonstrate for 
the first time that targeting PKA-mediated suppression of RhoA activity by genistein may be an 
important mechanism for its previously reported protective action against inflammation-related 
vascular dysfunction in vivo such as atherosclerosis (9–15, 17–20). 
Endothelial permeability is associated with a dramatic change in the structural integrity of the 
endothelial monolayer as well as actomyosin-based cell contractility regulated by the 
phosphorylation state of MLC (5). Indeed, phosphorylation of regulatory MLC is a key 
mechanism of EC contraction and thrombin-induced barrier dysfunction (5). In the present study, 
genistein suppressed the thrombin-induced phosphorylation of MLC in ECs, providing further 
evidence showing the protective action of genistein against endothelial barrier dysfunction. 
As genistein reportedly has both estrogenic and antiestrogenic actions in some tissues, which 
may largely be due to its binding activity to the ERs, which are present in ECs, we considered 
the possibility that the effect of genistein on endothelial permeability is mediated through the 
ER-mediated mechanism. However, blockage of ERs with ICI 182,780, a pure antagonist for 
both ERα− and ERβ by inhibiting receptor dimerization and inducing their degradation (33–35), 
did not inhibit the effect of genistein on vascular permeability. It is unlikely that the inability of 
this agent to block the effect of genistein on thrombin-induced barrier dysfunction is due to a 
lack of efficacy, because we recently reported that, at the same concentration used, ICI 
completely abolished the 17β-estradiol-elicited various biological events in ECs (23, 46). Indeed, 
a number of previous studies have shown that activation of these classical ERs by 17β-estradiol 
can disrupt cytoskeletal architecture and lead to increased EC monolayer permeability and 
migration (47–49), an effect that may involve the activation of RhoA signaling (48, 50), which 
was also inhibited by genistein in the present study. These results suggest that the effect of 
genistein on EC monolayer permeability provoked by thrombin is independent of the ER-
mediated signaling mechanisms. 
Genistein at high concentrations can inhibit PTK (36), and studies showed that activation of PTK 
may facilitate cell contraction and barrier dysfunction (51, 52). However, we do not believe that 
the activity of genistein on thrombin-induced endothelial barrier dysfunction is mediated through 
inhibition of PTK. First, genistein concentrations (0.1 to 10 μM) used in present studies that had 
protective effect of genistein against thrombin-induced endothelial barrier dysfunction had no 
effect on basal or agonist-stimulated PTK activity in ECs as we previously examined (29). 
Genistein inhibited PTK only in ECs at 100-μM concentration (29), which is as high as 10- to 
1000-fold of the effective doses of genistein used in the present study. Second, daidzein, an 
analog of genistein that does not inhibit PTK, also inhibit the effect of genistein on vascular 
permeability. 
Endothelial-derived NO regulates a variety of vascular functions including anti-inflammation 
(53, 54). It is well established that the thrombin-induced increase in intracellular [Ca2+] leads to 
the activation of Ca2+/calmodulin-dependent MLC kinase (MLCK), which subsequently 
phosphorylates Thr-18 and Ser-19 of MLC, a key mechanism of thrombin-induced EC barrier 
dysfunction. Genistein did not alter either resting [Ca2+] or thrombin-induced increase in 
Ca2+mobilization. These data suggest that the activity of genistein on thrombin-induced 
endothelial barrier dysfunction is not significantly mediated through modulation of intracellular 
[Ca2+]. Previous studies have shown that NO can reduce thrombin-induced endothelial 
permeability (35). We recently demonstrated that genistein stimulates rapid NO production via 
nongenomic activation of eNOS in ECs (29). In the present study, genistein action on thrombin-
induced EC permeability was only moderately attenuated by eNOS inhibitor L-NAME, although 
this dose of L-NAME completely blocked genistein-induced eNOS activity in ECs in our 
previous study (29). However, inhibition of NO production by L-NAME also enhanced the 
thrombin-induced increase in permeability. Interestingly, it was reported that thrombin can also 
increase rapid NO production by stimulating eNOS activity in ECs (55, 56). These findings 
suggest that the observed attenuating effect of L-NAME on barrier protective action of genistein 
is at least partially attributable to the inhibition of thrombin-induced NO production. The data 
from the present study also provide evidence that the elevated endogenous NO production by 
thrombin or genistein is insufficient to reverse thrombin-stimulated endothelial barrier 
permeability, and that there should be an alternative mechanism that is believed to play a more 
important role in mediating the protective effect of genistein in ECs. 
RhoA has been suggested to substantially mediate the thrombin-induced hyperpermeability of 
endothelium by various mechanisms (5, 39, 57–59). Once activated, RhoA activates its 
downstream target Rho kinase, which increases MLC phosphorylation by inactivation of myosin-
specific phosphatase (60, 61). Rho kinase also directly increases MLC phosphorylation and 
cytoskeletal reorganization (62). Actin-myosin contraction and subsequent EC barrier 
dysfunction are primarily mediated through MLC phosphorylation (60,61). In the present study, 
genistein ablated the activity of RhoA membrane translocation and MLC phosphorylation 
stimulated by thrombin, suggesting that genistein acts on the Rho/MLC signaling pathway to 
exert this cytoprotective action in ECs, a novel function of genistein that has not been previously 
recognized. 
It has been consistently shown that activation of the cAMP/PKA signaling pathway protects 
against endothelial barrier dysfunction promoted by various inflammatory mediators, including 
thrombin (39, 41–43, 63, 64). Indeed, we showed in the present study that elevation of 
intracellular cAMP concentration profoundly inhibited endothelial permeability, further 
confirming a critical role for cAMP in counteracting endothelial barrier dysfunction. Previous 
studies found that thrombin-induced intercellular gap formation is always paralleled by a rapid 
decrease in cAMP production in ECs, which is necessary for disrupting barrier function by this 
inflammatory mediator (65, 66). Thrombin may decrease cAMP levels by Ca2+ entry-mediated 
inhibition of type 6 adenylate cyclase (AC) (65). In the present study, thrombin greatly reduced 
intracellular cAMP levels in ECs, which was negated by treatment with genistein. This genistein 
effect is not due to the suppression of thrombin-stimulated intracellular [Ca2+] rise but rather a 
direct stimulation of cAMP production, because genistein alone elevated intracellular cAMP 
levels and our recent study shows that genistein can directly activate AC, leading to cAMP/PKA 
signaling in primary ECs (29). Accordingly, inhibition of PKA abolished the inhibitory effects of 
genistein on thrombin-induced EC permeability, MLC phosphorylation, and RhoA membrane 
translocation, and these PKA-mediated actions of genistein are mimicked by application of a 
cAMP analog. Taken all together, these results indicate that genistein ameliorates thrombin-
induced endothelial barrier dysfunction by activation of the AC/cAMP/PKA cascade, leading to 
inhibition of RhoA signaling in ECs (Figure 7). However, how AC is activated by genistein is 
unclear. The GTP-binding protein Gαs is often required for cell membrane receptor-mediated 
activation of AC (67, 68). Interestingly, it was shown that genistein can bind to an orphan plasma 
membrane receptor GPR30 in cancer cells (69). While the physiological role of GPR30 is still 
unclear, it was shown that GPR30 is coupled to Gαs to stimulate AC in cancer cells (67). 
Because GPR30 is also expressed in vascular ECs (70), there is a possibility that genistein 
activates AC via GPR30-mediated mechanisms. This aspect is currently under investigation in 
our laboratory. 
 
Figure 7. Schematic illustration of proposed mechanisms by which genistein protects against 
thrombin-induced endothelial barrier dysfunction. EC, endothelial cell; MLC, myosin light 
chain, PKA, protein kinase A. 
In summary, we showed that genistein inhibits thrombin-induced increase in endothelial 
monolayer permeability. This protective activity of genistein in EC-formed barrier is novel 
because it is not mediated through its known actions or inhibition of thrombin-induced increase 
in intracellular [Ca2+], but it depends on PKA-mediated suppression of RhoA activity. Given that 
EC inflammation and dysfunction play a critical role in the pathogenesis of various vascular 
diseases and that genistein exerts this protective effect on ECs at readily achievable 
concentrations by dietary intake of this compound, our findings may provide a novel cellular 
mechanism that may underlie some of the reported beneficial effects of genistein in modulation 
of vascular function. 
Abbreviations: 
AC adenylate cyclase 
avidin-FITC avidin conjugated fluorescein 
BAECs bovine endothelial cells 
C3 C3-transferase 
eNOS endothelial NO synthase 
ER estrogen receptor 
FBS fetal bovine serum 
ICI ICI 182,780 
L-NAME NG-nitro-L-arginine methyl ester 
MLC myosin light chain 
MLCK MLC kinase 
NO nitric oxide 
PKA protein kinase A 
PTK protein tyrosine kinase. 
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